Monoclonal antibody SZ168 targeting Podoplanin alleviates neuroinflammation by suppressing microglial Pyroptosis in cerebral Hemorrhage
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115201 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Shiyao Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The Fir…. Hauptthemen laut MEDLINE: Pyroptosis, Cerebral Hemorrhage, Microglia, Membrane Glycoproteins. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Neuroinflammation drives secondary brain injury after intracerebral hemorrhage (ICH). Podoplanin (PDPN), a transmembrane glycoprotein linked to inflammatory responses, is hypothesized to exacerbate neuroinflammation in ICH. We aimed to investigate whether targeting PDPN with the monoclonal antibody SZ168 mitigates neuroinflammation and brain injury via modulating microglial pyroptosis. METHODS: A collagenase-induced ICH model was established in C57BL/6 mice, randomized into Sham, ICH + mIgG, and ICH + SZ168 (intraperitoneal injection at 6 h post-ICH, 5 mg/kg daily). Neurological deficits, cerebral edema, blood-brain barrier (BBB) permeability, and hemorrhage volume were assessed. In vitro, human microglial HMC3 cells were stimulated with hemin (100 μM) and treated with SZ168 (0-50 μg). Microglial invasion, migration, proliferation, and pyroptosis-related proteins (NLRP3, cleaved caspase-1, GSDMD-N) were analysed via Transwell, scratch, CCK-8, and Western blot. RESULTS: SZ168 treatment improved neurological scores, reduced brain edema and hemorrhage volume, and preserved BBB integrity. In vitro, SZ168 dose-dependently suppressed microglial invasion, migration, and proliferation. Mechanistically, SZ168 downregulated NLRP3, cleaved caspase-1, and GSDMD-N, concomitant with reduced IL-1β and TNF-α levels. CONCLUSIONS: Targeting PDPN with SZ168 alleviates neuroinflammation and secondary brain injury post-ICH by inhibiting microglial pyroptosis via the NLRP3/Caspase-1/GSDMD pathway. These findings nominate SZ168 as a potential therapeutic agent for ICH. These findings suggest that PDPN is a potential target for the treatment of ICH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China, 215000; C…
- Department of Clinical Laboratory, Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai 200050, China.
- The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215006, Jiangsu, China. Electronic address: tutu0416@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Cui, J., Liang, R., Wang, X., & Zhao, Y. (2025). Monoclonal antibody SZ168 targeting Podoplanin alleviates neuroinflammation by suppressing microglial Pyroptosis in cerebral Hemorrhage. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115201
Vancouver
Liu S, Cui J, Liang R, Wang X, Zhao Y. Monoclonal antibody SZ168 targeting Podoplanin alleviates neuroinflammation by suppressing microglial Pyroptosis in cerebral Hemorrhage. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115201
BibTeX
@article{Liu2025,
author = {Liu, Shiyao and Cui, Jie and Liang, Ruyi and Wang, Xia and Zhao, Yiming},
title = {Monoclonal antibody SZ168 targeting Podoplanin alleviates neuroinflammation by suppressing microglial Pyroptosis in cerebral Hemorrhage},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115201}
}
EUVIMED